Observations placeholder

Ziprasidone – is marketed as Geodon  , or Zeldox. It is also approved for acute agitation in schizophrenic patients, acute treatment of mania and mixed states associated with bipolar disorder. As you can see it has a history of producing hallucinations.  It  acts at the following receptors and transporters – histamine, seretonin, adrenergic and anticholinergic, it has numerous other side effects.

o        D₂ Antagonist (K_i = 4.8 nM)
o        D₃ Antagonist (K_i = 7.2 nM)
o        5-HT_1A Agonist (K_i = 3.4 nM)
o        5-HT_1D Antagonist (K_i = 2.3 nM)
o        5-HT_2A Antagonist/Inverse Agonist (K_i = 0.4 nM)
o        5-HT_2C (K_i = 1.3 nM)
o        NET
o        SERT
o        H₁ Antagonist (K_i = 47 nM)
o        ?₁-adrenergic Antagonist (K_i = 10 nM)
o        mACh (IC₅₀ >1000 nM) [negligible affinity]

Quote “ Ziprasidone also displays some inhibition of synaptic reuptake of serotonin and norepinephrine, although the clinical significance of this is unknown”.  So if the clinical significance is unknown the effects will be unknown. And another quote “The mechanism of action of ziprasidone is unknown”.  If this were not enough Ziprasidone received a black box warning due to increased mortality in elderly patients with dementia-related psychosis.  It increases the risk of a potentially lethal type of heart arrhythmia known as torsades de pointes